Insulet (PODD)
Search documents
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
Zacks Investment Research· 2024-05-02 14:55
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What ar ...
Insulet (PODD) Outperforms Broader Market: What You Need to Know
Zacks Investment Research· 2024-04-26 23:16
Insulet (PODD) closed the most recent trading day at $166.19, moving +1.23% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.02%. Elsewhere, the Dow gained 0.4%, while the tech-heavy Nasdaq added 2.03%.The the stock of maker of insulin infusion systems has fallen by 4.22% in the past month, leading the Medical sector's loss of 5.2% and undershooting the S&P 500's loss of 3.15%.The upcoming earnings release of Insulet will be of great interest to investors. The company's ea ...
Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
Zacks Investment Research· 2024-04-24 13:46
Insulet (PODD) is scheduled to report first-quarter 2024 results on May 9 after market close.In the last reported quarter, the company’s adjusted earnings per share of $1.40 surpassed the Zacks Consensus Estimate by a remarkable 108.96%. Earnings beat estimates in each of the trailing four quarters, the average beat being 100.09%.Let’s take a look at how things have shaped up prior to this announcement.Factors at PlayIn 2023, Insulet firmly established itself as the market leader in automated insulin delive ...
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
Zacks Investment Research· 2024-04-12 17:16
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Insulet (PODD) , which belongs to the Zacks Medical - Products industry, could be a great candidate to consider.This maker of insulin infusion systems has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 93.23%.For the last repor ...
Here's Why You Should Buy Insulet (PODD) Stock Right Now
Zacks Investment Research· 2024-03-18 13:25
Insulet Corporation (PODD) is well-poised to gain in the coming quarters, backed by the strength of its revolutionary Omnipod 5 Automated Insulin Delivery (“AID”) system. The continued market expansion of Omnipod DASH is also highly encouraging. Strong solvency is an added upside. Meanwhile, the company’s sole dependency on the Omnipod system and intense competitive pressure remain concerns for its operations. In the past year, this Zacks Rank #2 (Buy) stock has decreased 47.9% against the 6.6% rise of t ...
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Zacks Investment Research· 2024-03-14 14:46
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...
Insulet's Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
Businesswire· 2024-03-08 11:00
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented positive results from its first randomized controlled trial (RCT) showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & T ...
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Businesswire· 2024-03-05 11:00
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will present new clinical evidence related to the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place March 6 – 9, 2024 in Florence, Italy, and online. “We are thrilled to unveil the results of our inaugural random ...
Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand
Zacks Investment Research· 2024-02-28 15:01
Insulet Corporation (PODD) reported adjusted earnings per share (EPS) of $1.40 for fourth-quarter 2023, which improved from the year-ago period’s adjusted EPS of 52 cents per share.Fourth-quarter 2023 adjusted earnings exceeded the Zacks Consensus Estimate of 67 cents by a huge 108.9%.The quarter’s adjustment excludes a charge associated with a voluntary medical device correction notice issued to replace the Omnipod DASH Personal Diabetes Managers.GAAP EPS for the quarter was $1.44 compared with 24 cents in ...
Down -15.31% in 4 Weeks, Here's Why You Should You Buy the Dip in Insulet (PODD)
Zacks Investment Research· 2024-02-27 15:36
Insulet (PODD) has been beaten down lately with too much selling pressure. While the stock has lost 15.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measu ...